The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
SGLT2 Inhibitors Provide Benefit Across Spectrum of Heart Failure, with Deepak Bhatt, MD
May 18th 2021An analysis of 9 trials examining SGLT2 inhibitors in patients with heart failure provides insight into the effects of the agents across the spectrum of heart failure, including those with decreased eGFR and preserved ejection fraction.
COVID-19 Has Increased Burnout, Desire for Career Change in Cardiology
May 17th 2021Results of a well-being study presented at ACC.21 paint a grim picture related to the impact of COVID-19 on burnout and well-being among cardiology professionals. We sat down with lead investigator Laxmi Mehta, MD, for further perspective on the issue.
FLOWER-MI: No Benefit to FFR-Guided PCI versus Angiography-Guided Procedure
May 16th 2021Data from the FLOWER-MI study suggest fractional flow reserve-guided PCI provided no benefit versus angiography-guided PCI for risk of death, MI, or urgent revascularization among STEMI patients with multivessel disease.
How STRENGTH Results Impact REDUCE-IT, with Deepak Bhatt, MD, MPH
May 16th 2021As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.